F. Blackhall Et Al. , "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9, pp.1547-1558, 2021
Blackhall, F. Et Al. 2021. Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9 , 1547-1558.
Blackhall, F., Jao, K., Greillier, L., Cho, B. C., Penkov, K., Reguart, N., ... Majem, M.(2021). Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9, 1547-1558.
Blackhall, Fiona Et Al. "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study," JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9, 1547-1558, 2021
Blackhall, Fiona Et Al. "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9, pp.1547-1558, 2021
Blackhall, F. Et Al. (2021) . "Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study." JOURNAL OF THORACIC ONCOLOGY , vol.16, no.9, pp.1547-1558.
@article{article, author={Fiona Blackhall Et Al. }, title={Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study}, journal={JOURNAL OF THORACIC ONCOLOGY}, year=2021, pages={1547-1558} }